New stock news | Bonasia submits listing application to the Hong Kong Stock Exchange Main Board

According to the disclosure on February 11 by the Hong Kong Stock Exchange, Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (referred to as Bonasia) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CISI FIN and ICBC International acting as its joint sponsors. The prospectus reveals that Bonasia is a clinical contract research organization (CRO) headquartered in Hangzhou, China, dedicated to leveraging digital empowerment for innovative drug clinical research. The company's core business is to provide clinical trial technical services for pharmaceutical and biotechnology companies at home and abroad, aiming to accelerate the research and commercialization process of chemical drugs and biologics.